ARTICLE | Company News
Invitae, Myriad Genetics, Pathway Genomics diagnostic news
February 9, 2015 8:00 AM UTC
Myriad reached settlements to dismiss litigation with Invitae and Pathway alleging that the companies’ assays infringed Myriad patents related to the breast cancer 1 early onset (BRCA1) and BRCA2 genes. Myriad promised not to sue the companies under the patents asserted in the litigation. Myriad filed the suit against Invitae in 2013 and the suit against Pathway in 2014, which were both transferred to the U.S. Judicial Panel on Multidistrict Litigation (see BioCentury, Dec. 9, 2013 & June 23, 2014). ...